Q-omics provides the consensus-scored CCR10 profile across patient tissues and cancer cell-line models. CCR10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCR10 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CCR10 RNA expression shows 15,330 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where CCR10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCR10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCR10 survival associations across molecular data types. CCR10 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCR10 RNA expression–survival associations across cancer types. High CCR10 expression shows unfavorable associations in KIRP, UVM, LIHC and KIRC, but favorable associations in HNSC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCR10 RNA expression.
This table summarizes CCR10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCR10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCR10 shows lower tumor expression in COAD, KICH and BRCA and higher tumor expression in KIRC, LIHC and THCA. The COAD box plot shows higher CCR10 RNA expression in normal versus tumor tissue (log2 FC = −0.971, t-test p < 0.001).
This table shows molecular features associated with CCR10 in patient tissues and cancer cell lines. In patient samples, CCR10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCR10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
